Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kevin Lundgren"'
Autor:
David J. Kwiatkowski, Guru Sonpavde, Toni K. Choueiri, Kent W. Mouw, Joaquim Bellmunt, Fei Dong, Mark Preston, Eliezer M. Van Allen, Lauren Harshman, Kevin Lundgren, Jaegil Kim, Renato Umeton, Amin H. Nassar
Histogram showing the distribution of alterations in KDM6A in males and females for 4 subtypes of urothelial carcinoma. Red bars are scaled to show the frequency (%) of female samples with an alteration in KDM6A; Gray bars are scaled to show the freq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a677537b5c4d4b2ef30c30784316038
https://doi.org/10.1158/1078-0432.22473353
https://doi.org/10.1158/1078-0432.22473353
Autor:
David J. Kwiatkowski, Guru Sonpavde, Toni K. Choueiri, Kent W. Mouw, Joaquim Bellmunt, Fei Dong, Mark Preston, Eliezer M. Van Allen, Lauren Harshman, Kevin Lundgren, Jaegil Kim, Renato Umeton, Amin H. Nassar
Purpose:The purpose of this study is to characterize the mutational landscape across the spectrum of urothelial carcinoma (UC) to identify mutational features and potential therapeutic targets.Experimental Design:Using targeted exome sequencing (n =
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37f4487c3c2582f4a19949765ed2daeb
https://doi.org/10.1158/1078-0432.c.6528488
https://doi.org/10.1158/1078-0432.c.6528488
Autor:
Joaquim Bellmunt, David J. Kwiatkowski, Kevin Lundgren, Amin Nassar, Mark A. Preston, Guru Sonpavde, Toni K. Choueiri, Kent W. Mouw, Jaegil Kim, Renato Umeton, Lauren C. Harshman, Eliezer M. Van Allen, Fei Dong
Publikováno v:
Clinical Cancer Research. 25:2458-2470
Purpose: The purpose of this study is to characterize the mutational landscape across the spectrum of urothelial carcinoma (UC) to identify mutational features and potential therapeutic targets. Experimental Design: Using targeted exome sequencing (n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781d5cc1aed25468b0666034de7eaf29
https://doi.org/10.1158/1078-0432.ccr-18-3147
https://doi.org/10.1158/1078-0432.ccr-18-3147
Autor:
Guru Sonpavde, Amin Nassar, Joaquim Bellmunt, Xiao X. Wei, Eliezer M. Van Allen, Bradley Alexander McGregor, Kevin Lundgren, David J. Kwiatkowski, Mark Pomerantz, Graeme S. Steele, Kent W. Mouw, Mark A. Preston, Lauren C. Harshman, Atish D. Choudhury, Toni K. Choueiri
Publikováno v:
JCO Precis Oncol
Purpose FGFR3-TACC3 (fibroblast growth factor receptor 3–transforming acidic coiled coil-containing protein 3) fusions have recently been identified as driver mutations that lead to the activation of FGFR3 in bladder cancer and other tumor types an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4a73ea0b9e6c8bb95eb3f96eeadf045
https://doi.org/10.1200/po.18.00013
https://doi.org/10.1200/po.18.00013
Autor:
Stephanie A. Wankowicz, Eliezer M. Van Allen, Dominick Bossé, Joaquim Bellmunt, Laura Polacek, Nikhil Wagle, Toni K. Choueiri, Sussana Jacobus, Lauren C. Harshman, Irene Moreno, Aly-Khan A. Lalani, Jonathan E. Rosenberg, Kevin Lundgren, David Y. Takeda
Publikováno v:
British Journal of Cancer
BACKGROUND: Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b205068f53d6e0aa82bcc8e1d1b18b75
https://doi.org/10.1038/s41416-018-0261-0
https://doi.org/10.1038/s41416-018-0261-0
Publikováno v:
Future Oncology. 13:2745-2758
Pembrolizumab is a humanized monoclonal antibody that targets PD-1. In the Phase III trial KEYNOTE-045, pembrolizumab was associated with a significant overall survival benefit when compared with docetaxel, paclitaxel and vinflunine in second line me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71f5297e843afcebc132bc047133b54e
https://doi.org/10.2217/fon-2017-0284
https://doi.org/10.2217/fon-2017-0284
Autor:
Matthew S. Farina, Kevin Lundgren, Elena Sevillano, Guillermo Velasco, Dominick Bossé, Aly-Khan A. Lalani, Joaquim Bellmunt, Lillian Werner, Stephanie A. Wankowicz, Aranzazu Gonzalez del Alba, Toni K. Choueiri
Publikováno v:
Clinical Genitourinary Cancer. 15:e1089-e1094
Background Upper tract urothelial carcinomas (UTUCs) are increasingly recognized as separate malignancies. Additional insight into clinical outcomes and key prognostic factors are needed. Objectives To detail outcomes of patients with UTUCs recurring
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::635e3a3a457368f7182e139dc2108318
https://doi.org/10.1016/j.clgc.2017.07.012
https://doi.org/10.1016/j.clgc.2017.07.012
Autor:
Toni K. Choueiri, Joaquim Bellmunt, David J. Kwiatkowski, Jaegil Kim, Amin Nassar, Guru Sonpavde, Kevin Lundgren
Publikováno v:
JCO Precis Oncol
Recent work has pointed to alterations in fibroblast growth factor receptors (FGFRs) as potential drivers of colder metastatic urothelial carcinoma (mUC) microenvironments.1,2 FGFRs mediate cell proliferation, migration, differentiation, and survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36c11c232b1dc2fe179a304a14df648b
https://europepmc.org/articles/PMC7885951/
https://europepmc.org/articles/PMC7885951/
Publikováno v:
Drugs. 77(10)
Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12–14 months for patients with advanced disease who have progressed on or re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b421559cf7ad8edc31fb28929bfecc3
https://pubmed.ncbi.nlm.nih.gov/28493171
https://pubmed.ncbi.nlm.nih.gov/28493171
Autor:
Thomas Powles, Lucia Carril, Parissa Alerasool, Pedro Isaacsson Velho, Guru Sonpavde, Min Yuen Teo, Rana R. McKay, Xiao X. Wei, Kevin Lundgren, Noah M. Hahn, Daniele Raggi, Vadim S. Koshkin, Ravi Kanesvaran, Daniel Castellano, Andrea Necchi, Joaquim Bellmunt, Laura Morrison, Jacob Gaines, Petros Grivas, Jonathan E. Rosenberg
Publikováno v:
Journal of Clinical Oncology. 36:e16517-e16517
e16517Background: PD-1/PD-L1 inhibitors or carbo-based chemo are both reasonable therapeutic options in the first-line setting for cisplatin-ineligible mUC pts. However, optimal first-line therapy and sequencing of these regimens is unclear. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d00f2b4109c5576aace97df7f6387c34
https://doi.org/10.1200/jco.2018.36.15_suppl.e16517
https://doi.org/10.1200/jco.2018.36.15_suppl.e16517